Genitope suspends MyVax development
USA-based Genitope Corp has suspended development of MyVax, its investigational personalized immunotherapy, and is evaluating its alternatives with respect to the other aspects of its business, including development of its monoclonal antibody program.
The firm made the announcement after a meeting with representatives of the US Food and Drug Administration to discuss the previously-announced results of a pivotal Phase III clinical trial of MyVax personalized immunotherapy in previously-untreated follicular B-cell non-Hodgkin's lymphoma patients. The study did not meet its primary endpoint - there was no statistically-significant difference in progression-free survival with the agent versus the control.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze